查看購物車
  • Simplified Chinese
  • Japanese
非滲出性視網膜疾病治療藥市場報告(2025年)
市場調查報告書
商品編碼
1849631

非滲出性視網膜疾病治療藥市場報告(2025年)

2025 Nonexudative Retinal Disease Pharmaceuticals Market Report
出版日期: | 出版商: Market Scope, LLC | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

新到信息

"非滲出性視網膜疾病治療市場報告（2025）" 提供了乾性老年黃斑部病變 (AMD) 和其他非滲出性視網膜疾病的最新疾病預測，並包含了補體抑制劑、基因治療藥物和其他新興治療類別的最新預測。

今年的報告追蹤了藥物遞送技術的進展，這些技術正在擴大臨床階段藥物開發計畫的範圍並提高治療的持久性。報告中還包含了美國醫生使用補體抑制劑經驗的最新調查數據，以及關於美國和西歐醫生如何看待和計劃採用基因治療技術的最新見解。

"2025年非滲出性視網膜疾病治療市場報告" 全面分析了當前及新興的干性老年黃斑變性 (AMD) 和其他非滲出性視網膜疾病的治療方法，並按地區進行了劃分。我們評估了補體抑制劑、基因療法、緩釋技術、抗氧化劑等，並檢視了關鍵市場趨勢、患者經濟狀況、報銷趨勢以及五年成長預測。

本報告也提供了詳細的銷售和價值需求預測、產品類別市場佔有率，並對19家主要競爭對手進行了概況介紹，探討了他們的策略和前景。

目錄

"2025年非滲出性視網膜疾病治療市場報告" 以清晰的數據為依據，展現了乾性老年性黃斑部病變 (AMD) 和其他非滲出性視網膜疾病治療領域不斷發展的格局。

主要內容：

  • 疾病概述與危險因子：探討非滲出性視網膜疾病，包括其病因、疾病進展及其與整體健康和生活方式的關係。
  • 診斷與治療現況：探討診斷技術、病患管理趨勢、藥物介入日益重要的角色。
  • 全球視網膜照護現況：概述全球視網膜照護服務、病患就醫途徑、專科醫師分佈、治療方案採納趨勢。
  • 現有療法：分析已核准的藥物和生物製劑、市場滲透率、定價趨勢、競爭格局等。
  • 在研藥物：回顧正在研發中的研究性藥物，這些藥物有望引領下一代治療，包括輔助抑制劑、基因療法和緩釋裝置。
  • 公司簡介及臨床前活動：介紹正在開發或銷售非滲出性視網膜疾病治療藥物的公司，以及其他進行臨床前計畫的公司。
簡介目錄

What's New:

The "2025 Nonexudative Retinal Disease Pharmaceuticals Market Report" features updated disease estimates for geographic atrophy and other nonexudative retinal conditions and fresh forecasts for complement inhibitors, gene therapies, and other emerging treatment classes.

This year's edition expands coverage of clinical-stage drug development programs and tracks progress in drug-delivery technologies designed to improve treatment durability. It also includes new survey data on US physician experience with complement inhibitors and updated insights into how doctors in the US and Western Europe view and plan to adopt gene therapy techniques.

The "2025 Nonexudative Retinal Disease Pharmaceuticals Market Report" delivers a comprehensive analysis of current and emerging therapies for geographic atrophy, dry AMD, and other nonexudative retinal diseases. It evaluates complement inhibitors, gene therapies, sustained-release technologies, antioxidants, and more-examining key market trends, patient economics, reimbursement dynamics, and five-year growth forecasts.

The report also includes detailed unit and dollar demand projections, product category market shares, and profiles of 19 leading competitors with insights into their strategies and outlooks.

Contents:

The "2025 Nonexudative Retinal Disease Pharmaceuticals Market Report" provides a clear, data-driven view of the evolving treatment landscape for geographic atrophy, dry AMD, and other nonexudative retinal diseases.

Coverage highlights include:

  • Disease overview and risk factors: discussion of nonexudative retinal diseases, their causes, disease progression, and links to systemic health and lifestyle.
  • Diagnosis and treatment landscape: examination of diagnostic technologies, patient management trends, and the growing role of pharmaceutical intervention.
  • Global retinal care environment: overview of global retinal care delivery, patient access, specialist distribution, and treatment adoption trends.
  • Current therapies in the market: analysis of approved pharmaceuticals and biologics, including market penetration, pricing dynamics, and competitive positioning.
  • Development pipeline: review of investigational agents in development-complement inhibitors, gene therapies, sustained-release devices, and more-shaping the next generation of care.
  • Company profiles and preclinical activity: profiles of companies developing or marketing therapies for nonexudative retinal disease, plus a listing of additional firms with preclinical programs.